ALTEOGEN Inc Cash Flow Conversion Efficiency
ALTEOGEN Inc cash flow conversion efficiency. Based on the latest financial reports, ALTEOGEN Inc (196170) has a cash flow conversion efficiency ratio of 0.030x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩16.56 Billion ≈ $11.22 Million USD) by net assets (₩547.25 Billion ≈ $370.86 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of ALTEOGEN Inc (2014–2025)
Cash flow conversion efficiency of ALTEOGEN Inc from 2014 to 2025. This chart illustrates how ALTEOGEN Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ALTEOGEN Inc stock quote for real-time trading data and today's change.
ALTEOGEN Inc Cash Flow Conversion Ratio Explained
ALTEOGEN Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
ALTEOGEN Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ALTEOGEN Inc ranked by their cash flow conversion efficiency. Also see ALTEOGEN Inc (196170) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Camden Property Trust
NYSE:CPT
|
0.036x |
|
BizLink Holding Inc
TW:3665
|
0.048x |
|
AtkinsRealis Group Inc
TO:ATRL
|
0.015x |
|
CHINA RE.PO.HO.UNS.ADR/15
F:CRP0
|
N/A |
|
Deutsche Lufthansa AG
XETRA:LHA
|
0.159x |
|
Boston Properties Inc
NYSE:BXP
|
0.020x |
|
Bentley Systems Inc
NASDAQ:BSY
|
0.158x |
|
WISE PLC SPONS.ADR/1
F:6WS0
|
N/A |
Annual Cash Flow Conversion Efficiency for ALTEOGEN Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of ALTEOGEN Inc from 2014 to 2025. Review ALTEOGEN Inc free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩454.44 Billion ≈ $307.97 Million |
₩124.13 Billion ≈ $84.12 Million |
0.273x | +41.14% |
| 2024-12-31 | ₩274.09 Billion ≈ $185.75 Million |
₩53.04 Billion ≈ $35.95 Million |
0.194x | +468.44% |
| 2023-12-31 | ₩147.84 Billion ≈ $100.19 Million |
₩-7.77 Billion ≈ $-5.26 Million |
-0.053x | +56.29% |
| 2022-12-31 | ₩148.76 Billion ≈ $100.81 Million |
₩-17.87 Billion ≈ $-12.11 Million |
-0.120x | -73.66% |
| 2021-12-31 | ₩136.73 Billion ≈ $92.66 Million |
₩-9.46 Billion ≈ $-6.41 Million |
-0.069x | -700.12% |
| 2020-12-31 | ₩131.16 Billion ≈ $88.89 Million |
₩1.51 Billion ≈ $1.02 Million |
0.012x | -91.17% |
| 2019-12-31 | ₩69.98 Billion ≈ $47.43 Million |
₩9.13 Billion ≈ $6.19 Million |
0.131x | +195.42% |
| 2018-12-31 | ₩66.63 Billion ≈ $45.15 Million |
₩-9.11 Billion ≈ $-6.18 Million |
-0.137x | -25.37% |
| 2017-12-31 | ₩39.85 Billion ≈ $27.00 Million |
₩-4.35 Billion ≈ $-2.95 Million |
-0.109x | -56.21% |
| 2016-12-31 | ₩45.23 Billion ≈ $30.65 Million |
₩-3.16 Billion ≈ $-2.14 Million |
-0.070x | -218.91% |
| 2015-12-31 | ₩38.55 Billion ≈ $26.13 Million |
₩2.26 Billion ≈ $1.53 Million |
0.059x | +73.87% |
| 2014-12-31 | ₩35.82 Billion ≈ $24.28 Million |
₩1.21 Billion ≈ $820.03K |
0.034x | -- |
About ALTEOGEN Inc
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the d… Read more